PAVmed reports former Exact Sciences CEO joins Lucid as vice chairman » 09:3807/2807/28/21
PAVmed Inc. (PAVM)…
PAVmed Inc. (PAVM) announced that medical diagnostics pioneer Stanley N. Lapidus, founder and former Chairman and CEO of Exact Sciences (EXAS), has joined its majority owned subsidiary Lucid Diagnostics as Vice Chairman of Lucid's Board of Directors.
|Over a week ago|
PAVmed's Lucid Diagnostics launches partnership with UpScriptHealth » 09:3207/2207/22/21
PAVmed announced that its…
PAVmed announced that its major subsidiary Lucid Diagnostics has entered into a definitive agreement with UpScriptHealth. Pursuant to the agreement, UpScript will support Lucid's upcoming EsoGuard Telemedicine Program by providing a Lucid-branded web-based telemedicine platform for patients with chronic heartburn symptoms to request video evaluation by a physician and, if clinically indicated, referral for Lucid's EsoGuard Esophageal DNA Test.
|Over a month ago|
Lucid Diagnostics completes CE Mark certification for EsoGuard Test » 09:3206/1006/10/21
PAVmed announced that its…
PAVmed announced that its major subsidiary, Lucid Diagnostics, has completed European IVDD CE Mark certification of its EsoGuard Esophageal DNA Test. Lucid and its EU authorized representative completed the EC declaration of conformity procedure, including the associated technical documentation, ensuring and declaring that EsoGuard meets the essential requirements of Europe's In-Vitro Diagnostic Medical Devices Directive 98/79/EC. EsoGuard may now be marketed in CE Mark European countries, which include the European Economic Area, Switzerland, and, until July 1, 2023, the United Kingdom.
PAVmed launches digital health company Veris Health » 09:3406/0206/02/21
PAVmed announced the…
PAVmed announced the launch of a new subsidiary, digital health company Veris Health, which acquired Oncodisc, a digital health company with tools to improve personalized cancer care through remote patient monitoring. Oncodisc was founded by experienced physician entrepreneurs, James Mitchell, M.D., who joins Veris as its full-time Chief Medical Officer, and Andrew Thoreson, M.D., who will serve as a Veris consultant. Oncodisc's core technologies include the first intelligent implantable vascular access port with biologic sensors and wireless communication, combined with an oncologist-designed remote digital healthcare platform that provides patients and physicians with new tools to improve outcomes and optimize the delivery of cost-effective care through remote monitoring and data analytics. Its groundbreaking vascular access port contains biologic sensors capable of generating continuous data on key physiologic parameters known to predict adverse outcomes in cancer patients undergoing treatment. Wireless communication to the patient's smartphone and its cloud-based digital healthcare platform efficiently and effectively delivers actionable real time data to patients and physicians. The technologies are the subject of multiple patent applications and one allowed patent awaiting final issuance. Veris is targeting FDA 510(k) clearance of the intelligent implantable vascular access port and launch of the remote digital healthcare platform for H2-2022. The planned Veris business model seeks to generate 100% recurring revenue through oncology practice and hospital-based subscriptions. These entities would purchase seats on the platform and pay a monthly remote monitoring charge to drive revenues from remote patient monitoring and device implantation under existing CPT codes, as well as established CMS Oncology Care Model bonuses and CMS Quality Reporting Program incentives. Veris also anticipates strong demand for its intelligent implantable vascular access port and remote monitoring platform from oncology biotherapeutic companies to support clinical trials of their novel immunotherapy and chemotherapy agents with continuous physiologic data and transformative analytics. PAVmed formed Veris Health Inc., a Delaware Corporation, as a wholly owned subsidiary, which in turn entered into a Stock Purchase Agreement to acquire 100% of the outstanding shares of Oncodisc Inc. from Oncodisc Holdings LLC, including all of Oncodisc's intellectual property, hardware, and software assets. In exchange, PAVmed granted Oncodisc Holdings LLC a 19.6% equity interest in Veris and provided $155,250 in cash to pay off two Oncodisc convertible notes. No additional cash consideration or PAVmed stock consideration was provided. A Shareholder Agreement between the parties provides additional terms and conditions concerning certain regulatory and commercial milestones, anti-dilution protection and other customary provisions. PAVmed will manage Veris through a Management Services Agreement until such time that the Veris Board of Directors decides to engage a dedicated management team and will finance its operations through intercompany advances until Veris decides to raise its own capital. Mitchell and Thoreson have entered into employment and consulting agreements, respectively, which include stringent intellectual property assignment and non-compete provisions.
PAVmed's Lucid Diagnostics receives CE Mark certification for EsoCheck device » 09:3605/2605/26/21
PAVmed and its major…
PAVmed and its major subsidiary Lucid Diagnostics announced that Lucid's EsoCheck Esophageal Cell Collection Device with Collect+Protect technology has received CE Mark certification. EU-based Notified Body TundefinedV Rhineland LGA Products GMBH issued a CE Certificate, effective May 24, 2021, declaring that EsoCheck conforms to the essential requirements of Medical Device Directive 93/42/EEC. With CE Mark secured, EsoCheck may now be marketed in CE Mark European countries, which include the European Economic Area, Switzerland, and, until July 1, 2023, the United Kingdom.
PAVmed receives CE Mark for CarpX minimally invasive carpal tunnel device » 09:3105/2505/25/21
PAVmed announced that it…
PAVmed announced that it has received CE Mark certification for its CarpX minimally invasive carpal tunnel device. EU-based Notified Body TundefinedV Rhineland LGA Products GMBH issued a CE Certificate, effective May 24, declaring that CarpX conforms to the essential requirements of Medical Device Directive 93/42/EEC. With CE Mark secured, CarpX may now be marketed in CE Mark European countries, which include the European Economic Area, Switzerland, and, until July 1, 2023, the United Kingdom.
|Over a quarter ago|
Largest borrow rate increases among liquid names » 08:4504/2804/28/21
WRAP, GALT, WPRT, SUNW, DNN, REI, PAVM, MAXN, OGI
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: Silver Spike Acquisition Corp (SSPK) 12.96% +0.65, Wrap Technologies (WRAP) 14.98% +0.43, Galectin Therapeutics (GALT) 21.63% +0.37, Westport (WPRT) 4.57% +0.36, Sunworks (SUNW) 7.26% +0.32, Denison Mines (DNN) 2.58% +0.32, Ring Energy (REI) 2.62% +0.29, PAVmed (PAVM) 2.18% +0.24, Maxeon Solar Technologies (MAXN) 4.75% +0.21, and Organigram Holdings (OGI) 3.16% +0.17.
In-the-money call buyers in PAVmed as shares bounce and volatility spikes » 10:1004/0704/07/21
In-the-money call buyers…
In-the-money call buyers in PAVmed as shares bounce and volatility spikes. Shares of the medical device maker up a dime, or 1.6%, near $6.33 this morning after an early dip below $6, with 5600 calls trading in the first 20 minutes, vs 330 puts, and buyers focused on the April 5 calls, bought in a number of sweeps around 9:45am ET from 1.36 to 1.56 as shares lifted from $6.17 to $6.28. Implied volatility up nearly 40 points in the April term to 172%.
PAVmed initiated with an Overweight at Cantor Fitzgerald » 16:4703/2903/29/21
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Kyle Mikson initiated coverage of PAVmed with an Overweight rating and $8 price target. The analyst is citing the company's "unique" business model emphasizing capital efficiency and speed to market for its medical device products. Mikson adds that PAVmed's subsidiary Lucid Diagnostics could enable widespread BE-EAC screening, which he sees as a "large unmet need".
Three new option listings and two option delistings on February 25th » 08:3002/2502/25/21
PAVM, HMI, SNSS
New option listings for…
New option listings for February 25th include PAVmed (PAVM), Viracta Therapeutics Inc (VIRX), and Zepp Health Corporation (Class A ADS) (ZEPP). Option delistings effective February 25th include Huami Corporation (Class A ADS) (HMI) and Sunesis Pharmaceuticals Inc (SNSS).